AI Article Synopsis

  • * A reported case involved a patient with RM who also had SLE and primary hypothyroidism, showing significant hyperpigmentation that improved after 14 months of treatment.
  • * The underlying causes of RM remain unclear, with potential contributing factors such as exposure to certain chemicals; the case suggests RM may represent a rare skin manifestation of autoimmunity, especially in conjunction with other autoimmune diseases.

Article Abstract

Introduction: Riehl's melanosis (RM) is an acquired hyperpigmentation disorder, presenting diffused and reticulate brownish-gray pigmentation, preferentially on the face and neck. RM overlaps with systemic lupus erythematosus (SLE) and Hashimoto's thyroiditis has never been reported.

Case: We report a case of RM patient accompanied with SLE and Hashimoto's thyroiditis of primary hypothyroidism. Progressing, diffuse, symmetric, and reticular hyperpigmentation was seen on the face, neck, and upper limbs, manifesting as typical melanosis. Skin microscopy showed diffuse black-pepper-like changes and telangiectasias. The diagnosis of SLE and primary hypothyroidism were confirmed by follow-up investigations. The hyperpigmentation turned notably lighter after 14 months of treatment with prednisone, hydroxychloroquine, and L-thyroxine.

Discussion: The exact pathogenesis of RM is unclear and exposure to coal tar dyes, ultraviolet, and fragrance fixatives in cosmetics are believed to be contributing factors, while some cases involve no triggers. It is not impossible that RM is a rare skin manifestation of SLE that has never been reported. The skin hyperpigmentation in this patient was not triggered by thyroid disease.

Conclusion: RM could be a skin manifestation of autoimmunity. Coexistence of RM, lupus erythematosus and thyroiditis in the same patient is rare and has never been reported.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9467848PMC
http://dx.doi.org/10.2147/CCID.S376614DOI Listing

Publication Analysis

Top Keywords

lupus erythematosus
12
riehl's melanosis
8
erythematosus thyroiditis
8
thyroiditis patient
8
face neck
8
sle hashimoto's
8
hashimoto's thyroiditis
8
primary hypothyroidism
8
skin manifestation
8
coexistence riehl's
4

Similar Publications

Systemic lupus erythematosus (SLE) is an autoimmune disease that more commonly affects African American people, although it is seen in people of all racial backgrounds. This condition is characterized by a dysregulated immune response resulting in widespread inflammation. Clinical manifestations caused by this inflammation include arthritis, anemia, cutaneous rashes, pleuritis, and nephritis.

View Article and Find Full Text PDF

Treatment of discoid lupus erythematosus scarring alopecia with deucravacitinib: A case report.

SAGE Open Med Case Rep

January 2025

Division of Dermatology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.

Discoid lupus erythematosus is a chronic, recurring, autoimmune skin disease causing annular, scarring plaques on the head and neck. Deucravacitinib, a tyrosine kinase 2 inhibitor in the Janus kinase inhibitor family, represents an emerging treatment option in systemic lupus erythematosus with potential applicability to discoid lupus erythematosus. We describe a 48-year-old woman with multiple treatment-refractory scalp plaques and associated alopecia treated with deucravacitinib.

View Article and Find Full Text PDF

Future atherosclerotic cardiovascular disease in systemic lupus erythematosus based on CSTAR (XXVIII): the effect of different antiphospholipid antibodies isotypes.

BMC Med

January 2025

Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Peking Union Medical College and Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, No. 1 Shuaifuyuan, Wangfujing Ave, Beijing, 100730, China.

Background: Patients with systemic lupus erythematosus (SLE) suffered from an increasing risk of cardiovascular diseases. In this multi-center prospective study, we aimed to determine the association between antiphospholipid antibodies (aPLs) and future atherosclerotic cardiovascular disease (ASCVD) in SLE.

Methods: In total, 1573 SLE patients were recruited based on the Chinese SLE Treatment and Research group (CSTAR) registry.

View Article and Find Full Text PDF

Efficacy of valaciclovir in preventing herpes zoster in patients receiving anifrolumab.

RMD Open

January 2025

Assistance Publique-Hôpitaux de Paris (AP-HP), Groupement Hospitalier Pitié-Salpêtrière, Centre de Référence des maladies auto-immunes et auto-inflammatoires systémiques rares de l'adulte d'Ile-de-France, Centre et Martinique, Service de Médecine Interne 2, Institut E3M, Paris, France, paris, France.

View Article and Find Full Text PDF

The morphological spectrum of cheilitis.

J Am Acad Dermatol

January 2025

Department of Dermatology and Venereology, AIIMS, Bhubaneswar, India. Pin-751019.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!